Amarin Corp. plc's sale of $400 million in American depositary shares (ADSs) ahead of the Sept. 28 PDUFA date for Vascepa (icosapent ethyl) boosted investor confidence while sparking buzz about another player in the space: Acasti Pharma Inc., of Laval, Quebec, which has a krill oil-based product due to report pivotal data soon.

Tonix Pharmaceuticals Holding Corp., of New York, said it closed an underwritten public offering of 9 million shares at 60 cents each, for total gross proceeds of approximately $5.4 million.

DUBLIN – To no one's great surprise, the underwriters of Genmab A/S's IPO on Nasdaq exercised their overallotment option, the company announced Friday, taking the total gross to $581.8 million. The Copenhagen-based antibody developer priced the offering of about 32.8 million American depositary shares at $17.75 Thursday. The stock (NASDAQ:GMAB) ended the week at $18.10.

LONDON – Medicxi has closed a €400 million (US$449 million) third fund, bringing the amount raised by the venture capital firm since it split off from its parent Index Ventures three years ago, to more than $1 billion.

Kronos Bio Inc. closed a $105 million series A preferred stock financing, shored up by a board composed of longtime pharma executives that includes the company CEO and president, Norbert Bischofberger, the former Gilead Sciences Inc. R&D executive vice president and chief science officer.

Obseva SA, of Geneva, said its board approved an increase of its share capital from 45.5 million shares to 48.6 million. The shares will be listed on the SIX Swiss Exchange on or around July 23.

Xenetic Biosciences Inc., of Framingham, Mass., priced a public offering of 2.3 million shares and warrants to purchase up to 2.3 million shares.

HONG KONG – Biocure Technology Corp., a Canadian biopharmaceutical company focusing on biosimilar products, is advancing a CAR T product through its South Korean subsidiary, Biocurepharm Inc., thanks to a recently closed private placement.

Gns Healthcare landed $23 million in a series D fundraising round led by Cigna Ventures. Cigna's wholly owned corporate venture fund joined Amgen Ventures, Celgene Corp., Echo Health Ventures, Alexandria Venture Investments and Gary Loveman, former Caesar's CEO and Aetna division president, in the latest round.

Eyenovia Inc., of New York, said it closed its underwritten public offering of 4.38 million shares of common stock at $2.78 each for net proceeds of approximately $11.2 million.